Profile Response Detail

Molecular Profile ALK rearrange ALK I1171T
Therapy Crizotinib
Indication/Tumor Type lung adenocarcinoma
Response Type resistant
Create By c-seddy
Update By spatt

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ALK rearrange ALK I1171T lung adenocarcinoma resistant Crizotinib Clinical Study Actionable In a clinical case study, a patient with a lung adenocarcinoma tumor harboring an ALK rearrangement and ALK I1171T progressed on Xalkori (crizotinib) therapy after 8 months and resistance was confirmed using cell culture with cells derived from the patient's tumor (PMID: 25228534). 25228534
PubMed Id Reference Title Details
(25228534) Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Full reference...